Compare Amylx Pharmaceuticals Inc (AMLX) vs Plby Group Inc (PLBY) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

PLBY trades at $1.16 with no recent price movement, showing technical bearish signals despite oversold RSI readings. The company has shown improving fundamentals with revenue stabilizing around $120-122 million and narrowing losses from -$278M in 2022 to -$13M in 2025. Recent positive developments include Russell index inclusion and a strategic share repurchase program. Operating cash flow turned positive in 2025 after years of negative performance, though the company maintains high debt levels with a debt-to-asset ratio of 59.52%.

While PLBY shows operational improvement and strong analyst support (75% buy ratings), significant risks remain including negative shareholder equity, high debt burden, and inconsistent earnings performance. The stock presents a turnaround opportunity if management can sustain EBITDA growth and debt reduction, but requires careful monitoring of cash flow sustainability and licensing revenue stability.